Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and durvalumab induction before chemoradiotherapy and/or resection in locally advanced NSCLC
NL-OMON55743Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of tremelimumab and durvalumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (4 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoint: Safety. Started Jan 2019; status: completed.
02
Drugs
tremelimumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON55743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55743.